Nupam P. Mahajan, Ph.D.

Urologic Surgery

Molecular Genetics and Genomics Program
Molecular Cell Biology Program
Biochemistry, Biophysics, and Structural Biology Program
Biomedical Informatics and Data Science Program

  • 314-273-7727

  • 314-273-7759

  • 314-272-7771

  • 6th Floor, Cancer Research Building, 660 S. Euclid Ave. St. Louis, MO, 63110-1093




  • How tyrosine phosphorylation regulates epigenetic processes that affect cellular homeostasis and cancer cell survival

Research Abstract:

A major interest in our lab is to determine how tyrosine phosphorylation regulates epigenetic processes that affect cellular homeostasis and cancer cell survival. We employ multiple tyrosine kinases to investigate these processes. The examples are:
- ACK1 (TNK2) : An oncogene with novel epigenentic activity in prostate, breast & lung cancers

- WEE1 : A novel epigenetic modulator & its significance in various malignancies

- ABL1 : A proto-oncogene with nuclear tyrosine kinase activity

Selected Publications:

Expression of FGD4 positively correlates with the aggressive phenotype of prostate cancer.
Bossan A, Ottman R, Andl T, Hasan MF, Mahajan N, Coppola D, Chakrabarti R.
BMC Cancer. 2018 Dec 17;18(1):1257. doi: 10.1186/s12885-018-5096-9.
PMID: 30558664

Blockade of ACK1/TNK2 To Squelch the Survival of Prostate Cancer Stem-like Cells.
Mahajan NP, Coppola D, Kim J, Lawrence HR, Lawrence NJ, Mahajan K.
Sci Rep. 2018 Jan 31;8(1):1954. doi: 10.1038/s41598-018-20172-z.
PMID: 29386546

WEE1 epigenetically modulates 5-hmC levels by pY37-H2B dependent regulation of IDH2 gene expression.
Mahajan NP, Malla P, Bhagwat S, Sharma V, Sarnaik A, Kim J, Pilon-Thomas S, Weber J, Mahajan K.
Oncotarget. 2017 Nov 10;8(63):106352-106368. doi: 10.18632/oncotarget.22374. eCollection 2017 Dec 5.
PMID: 29290954

ACK1/TNK2 Regulates Histone H4 Tyr88-phosphorylation and AR Gene Expression in Castration-Resistant Prostate Cancer.
Mahajan K, Malla P, Lawrence HR, Chen Z, Kumar-Sinha C, Malik R, Shukla S, Kim J, Coppola D, Lawrence NJ, Mahajan NP.
Cancer Cell. 2017 Jun 12;31(6):790-803.e8. doi: 10.1016/j.ccell.2017.05.003.
PMID: 28609657

The non-receptor tyrosine kinase TNK2/ACK1 is a novel therapeutic target in triple negative breast cancer.
Wu X, Zahari MS, Renuse S, Kelkar DS, Barbhuiya MA, Rojas PL, Stearns V, Gabrielson E, Malla P, Sukumar S, Mahajan NP, Pandey A.
Oncotarget. 2017 Jan 10;8(2):2971-2983. doi: 10.18632/oncotarget.13579.
PMID: 27902967

Last Updated: 8/14/2019 3:29:22 PM

Back To Top

Follow us: